Cancer Family
Transitional Cell Neoplasm
CI-CAN-00000374Explore in graph →
Non-malignant254 active trials5 approved drugs23 evidence items
- NCIt
- C6783
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000374Explore in graph →
Clinical trials
753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02500121 | Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | completed | Phase 2 | 108 | Matthew GalskyOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 |
| clinicaltrials |
| NCT03558503 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer(OPTIMA II) | completed | Phase 2 | 63 | UroGen Pharma Ltd.INDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT00238420 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Jul 19, 2022 | clinicaltrials |
| NCT01524991 | First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | completed | Phase 2 | 36 | Hoosier Cancer Research NetworkOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | completed | Phase 2 | 200 | Noah Hahn, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03945084 | Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy | completed | Phase 2 | 58 | University of Turin, ItalyOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT03051373 | Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract | completed | Phase 2 | 108 | Chinese PLA General HospitalOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT02788201 | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2020 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT00722553 | Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | completed | Phase 2 | 30 | Acrotech Biopharma Inc.INDUSTRY | 6 | Dec 17, 2019 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT02665039 | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function(VINGEM) | completed | Phase 2 | 62 | Dr Anders UllénOTHER | 2 | Oct 8, 2019 | clinicaltrials |
| NCT02351739 | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer(KEYNOTE143) | completed | Phase 2 | 78 | Acerta Pharma BVINDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03507166 | A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer | completed | Phase 2 | 43 | RemeGen Co., Ltd.INDUSTRY | 1 | Aug 21, 2019 | clinicaltrials |
| NCT00993616 | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02109328 | Alisertib in Chemotherapy-pretreated Urothelial Cancer | completed | Phase 2 | 22 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT01529411 | Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer(MAJA) | completed | Phase 2 | 86 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT00939809 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01668459 | Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel(CabB1) | completed | Phase 2 / Phase 3 | 20 | Dr Anjali ZarkarOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT00880334 | Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC | completed | Phase 2 | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Oct 9, 2017 | clinicaltrials |
| NCT02236195 | Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes | completed | Phase 2 | 17 | Mirati Therapeutics Inc.INDUSTRY | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01328574 | TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT00683059 | Single Agent Abraxane as Second Line Therapy in Bladder Cancer | completed | Phase 2 | 48 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00588666 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT01599013 | JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin(JASINT1) | completed | Phase 2 | 69 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT00059787 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00633789 | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | completed | Phase 2 | 597 | Bristol-Myers SquibbINDUSTRY | 9 | Oct 9, 2015 | clinicaltrials |
| NCT01600339 | A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) | completed | Phase 2 | 19 | Rambam Health Care CampusOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT01490437 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma(PECULIAR) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00714025 | A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy | completed | Phase 2 | 40 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jan 24, 2012 | clinicaltrials |
| NCT00101608 | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 15 | Mar 2, 2010 | clinicaltrials |
| NCT00077688 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 44 | Achieve Life SciencesINDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00191971 | 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen | completed | Phase 2 | 40 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 6, 2007 | clinicaltrials |
| NCT00154687 | Weekly TP-HDFL in the Treatment of Advanced TCC | completed | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Jul 31, 2007 | clinicaltrials |
| NCT00173862 | Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC | completed | Phase 2 | 18 | National Taiwan University HospitalOTHER | 1 | Jul 25, 2007 | clinicaltrials |
| NCT00101842 | Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer | completed | Phase 1 / Phase 2 | 61 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 29, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Sep 30, 2022source: clinicaltrials